Guardant Health, Inc. announced the launch of the Guardant Hereditary Cancer test, a germline test designed to identify genetic variants associated with cancer risk. This new offering aims to help cancer care teams provide optimal patient care by informing genetically targeted treatment and identifying at-risk relatives.
The blood-based panel test identifies guideline-recommended genetic variants across 82 genes linked to an increased risk for over 12 tumor types, including breast, colorectal, prostate, and endometrial cancers. This expands Guardant's portfolio to support healthcare providers across the entire continuum of cancer care.
Helmy Eltoukhy, Guardant Health chairman and co-CEO, stated that this is an important step in conquering cancer with data, allowing access to a broader set of precision oncology tools through a single source. The test requires a simple blood draw and results are available in two to three weeks, offering convenience and timely insights for personalized treatment plans.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.